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1 Drug description 
Generic/Brand name/ATC code:  
Nivolumab/Opdivo®/none 
Developer/Company:  
Nivolumab was developed as a collaboration between Ono Pharmaceutical 
and Medarex. Medarex was acquired by Bristol-Meyers Squibb (BMS) in 
2009. Ono Pharmaceutical and BMS have a strategic collaboration agreement 
to jointly develop and commercialise all collaboration products [1]. 
Description:  
The programmed cell death receptor-1 protein (PD-1) is expressed on a num-
ber of cell types, including activated T-cells, activated B-cells and natural 
killer cells. It acts as part of an immune checkpoint inhibition. Its main en-
dogenous ligands PD-L1 and PD-L2 are expressed in activated immune cells 
and in many tumour cells in response to inflammatory stimuli. Tumours 
have shown to escape immune surveillance by expressing PD-L1 and PD-L2, 
whereby suppressing tumour-infiltrating lymphocytes via PD-1/PD-L1,2 in-
teractions and preventing immune-mediated rejection of the tumour. Nivolu-
mab is a fully human IgG4 monoclonal antibody that blocks binding of PD-1 
to PD-L1. The inhibition of these interactions has demonstrated to enhance 
T-cell response and cell-mediated immune response against tumour cells [2–6].  
Nivolumab is administered as an intravenous infusion over 60 minutes at a 
dose of 3 mg per kilogram of body weight every two weeks [7]. 
 
 
2 Indication 
Nivolumab is intended to be used as single-agent first-line therapy for the 
treatment of unresectable or metastatic melanoma. 
 
 
3 Current regulatory status 
In Europe, nivolumab is under evaluation for a centralised marketing authori-
sation by the European Medicines Agency (EMA) [8]. Its request for an ac-
celerated assessment has been accepted for first- and second-line treatment 
of advanced (unresectable or metastatic) melanoma [9]. In addition, an ap-
plication was submitted for non-small cell lung cancer [1].  
Nivolumab, under the trade name Opdivo®, was approved under accelerated 
approval by the FDA in December 2014 for the treatment of patients with 
unresectable or metastatic melanoma and disease progression following ipili-
mumab and, if BRAF V600 mutation-positive, a BRAF inhibitor [7]. 
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In 2013, the FDA granted fast track designation for Opdivo® not only in mel-
anoma, but also in non-small cell lung cancer (NSCLC) and renal cell carci-
noma (RCC). In May 2014, breakthrough therapy designation for Opdivo® 
was granted for the treatment of patients with Hodgkin lymphoma after fail-
ure of autologous stem cell transplant and brentuximab [1]. 
 
 
4 Burden of disease 
Melanoma is a malignant tumour that begins in the melanocytes. It repre-
sents less than 2% of all skin cancers, but causes the majority of skin cancer-
related deaths [10; 11]. According to the WHO, 132,000 melanoma skin can-
cers occur globally each year, and the global incidence of melanoma contin-
ues to increase [12]. In Germany, approx. 19,200 and in Austria nearly 1,500 
new cases of melanoma skin cancer were diagnosed in the year 2010. In both 
countries, men and women were equally affected [13; 14]. 
Since the 1980s, age-adjusted incidence rates have risen markedly in western 
industrialised countries. By 2010, two years after introduction of a skin can-
cer screening program, there were 9,580/9,640 new cases in 2010 in German 
women and men, amounting to 23.0/24.0 new cases per 100,000 persons. The 
age-adjusted incidence rate was 17.8 for German women and 18.0 for German 
men (per 100,000, age-adjusted to the former European population). In Aus-
tria there were 723/785 new cases in Austrian women and men in 2010, equal-
ling 16.9/19.3 new cases per 100,000 persons (own calculations). The average 
age of cancer onset was 58 years in German women and 66 years in men. 
Over the preceding decade, age-adjusted mortality rates were nearly constant 
in Germany, ranging at 2.8 in men and 1.6 in women in 2010. That same year 
the rate was 3.0 in Austrian men and 2.0 in Austrian women [13–15]. Where-
as melanoma is one of the most common types of cancer in young adults, mel-
anoma is most frequently diagnosed amongst people aged 55–64 years [10; 16]. 
Risk factors for melanoma include genetic and environmental factors, such 
as sun exposure, pigmentary characteristics, multiple nevi, family and person-
al history of melanoma, immunosuppression and environmental exposures 
[10]. 
Signs and symptoms of melanoma include a change in the appearance of a 
mole or a pigmented area, a mole that itches, bleeds or is ulcerated, and the 
occurrence of satellite moles [10].  
According to the 2010 TNM staging system, patients are grouped into prog-
nostic categories based on the primary tumour (T) and the presence of re-
gional lymphatic (N) and distant metastases (M): Stage I is limited to low-
risk primary melanomas without evidence of regional or distant metastases 
(T1a-T2a). Stage II includes melanomas at higher risk of recurrence without 
regional or distant metastases (T2b-T4b). Stage III includes melanomas with 
involvement of lymph nodes or the presence of in-transit or satellite metas-
tases (N1-N3). Stage IV is defined by the presence of distant metastases (M). 
According to the AJCC staging system, localised disease include stages I-II, 
regional diseases stage III and distant metastatic disease stage IV [17].  
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Other prognostic factors include age, gender, pathologic factors (such as the 
involvement of the sentinel lymph node, growth pattern, lymphatic invasion), 
serum s-100 protein and gene expression profiling and proteomics [18].  
The outcome of melanoma of the skin depends on the stage at diagnosis. It is 
estimated that 82–85% of patients present with localised disease, 10–13% with 
regional and 2–5% with distant metastatic disease. Five-year survival rates 
are high at an early stage, but range from 20–70% in stage III to less than 
10% in stage IV [17].  
 
 
5 Current treatment 
For patients with advanced (unresectable or metastatic) melanoma, treatment 
options include surgical metastasectomy, immunotherapy, targeted inhibition 
of the mitogen-activated protein kinase (MAPK) pathway, radiation therapy 
and chemotherapy. Treatment depends on whether the disease is limited and 
resectable or disseminated and unresectable. If feasible, resection is recom-
mended for limited metastatic disease, and can delay the need for systemic 
treatment [17; 18].  
With the approval of novel treatments, the choice and sequencing of system-
ic therapy has changed. Prior to the authorisation of ipilimumab and vemu-
rafenib in the EU in the 2011 and 2012 respectively [19; 20], cytotoxic chem-
otherapy (e.g., dacarbazine) was widely used, despite not having proven to 
improve overall survival in patients with advanced melanoma [21]. 
To date, the choice of first-line systemic therapy depends on factors such as 
mutations in the MAPK pathway, the tempo of disease and the presence of 
cancer-related symptoms [17].  
Immunotherapy plays an important role in the treatment of advanced mela-
noma and has the potential for long-term disease control. Regimens include 
checkpoint inhibition with a monoclonal antibody against the negative regu-
latory molecule cytotoxic T-lymphocyte protein 4 (CTLA4) and monoclonal 
antibodies against PD-1 and its ligands, as well as high-dose interleukin-2 
(IL-2). The anti-CTLA4 antibody ipilimumab is approved for previously 
treated and untreated patients with advanced melanoma and is the first drug 
that has shown to improve overall survival in metastatic melanoma. It comes 
with an only modest chance of response, but with the possibility for some pa-
tients to remain alive over a longer period of time. There are no biomarkers 
that help to select patients most likely to respond to treatment and the onset 
of response might be delayed. Furthermore, significant immune-related ad-
verse events (irAEs) need to be taken into consideration. High-dose IL-2 is 
associated with an overall response rate of about 16% and long-term disease-
free survival in a small share of treated patients. Due to its toxicity, however, 
it is only an option for patients with good organ function. It is not author-
ised for melanoma in the EU. At the end of 2014, the anti-PD-1 antibodies 
nivolumab and pembrolizumab were approved in the US for patients that 
have progressed on ipilimumab and (if BRAF V600 mutation was present) a 
BRAF inhibitor [3; 17; 18; 21–24].  
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Approximately one-half of the patients with advanced melanoma have a BRAF 
V600 mutation that activates the MAP kinase (MAPK) pathway. In patients 
with metastatic melanoma and BRAF V600 mutation, the BRAF inhibitor ve-
murafenib increases overall survival, with high overall response rates of ap-
prox. 50%, while treatment is mostly well-tolerated. Other MAPK inhibitors 
include the BRAF inhibitor dabrafenib and the MEK1 and MEK2 inhibitor 
trametinib. MEK are downstreams of BRAF in the MAPK signal transduc-
tion pathway. With BRAF inhibitors, however, the treatment to maintain re-
sponse is necessary and most tumours become resistant after a median of six 
months. To address resistance, clinical trials of the combination of BRAF 
and MEK inhibitors have been conducted, showing that the combinations of 
dabrafenib plus trametinib and of vemurafenib plus cobimetinib yielded long-
er PFS and OS than treatment with a single BRAF inhibitor. The combina-
tion of BRAF and MEK inhibitors will thus very likely be the new standard 
therapy for patients with BRAF mutations [4; 17; 18; 21; 24–28].  
Radiation therapy to symptomatic sites of metastases may achieve good pal-
liation. Stereotactic radiosurgery may be particularly important in the man-
agement of brain metastases [18]. 
 
 
6 Evidence 
In addition to a free text search, a systematic literature search was conduct-
ed in Embase, Ovid Medline, CRD Database and the Cochrane Library. In 
total, 267 references were identified. The manufacturer provided one further 
publication which had already been identified by the systematic literature 
search. Regarding the reviewed indication – the first-line treatment for un-
resectable or metastatic melanoma – one phase III trial was identified [29].  
 
 
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Nivolumab in previously untreated melanoma without BRAF mutation [29] 
Study  
identifier 
Study ID Number: CA209-066 
ClinicalTrials.gov Identifier: NCT01721772 (CheckMate 066) 
EudraCT No.: 2012-003718-16 
Design Phase III, randomised (1:1), double-blind, active comparator, parallel assignment,  
multi-centre 
Duration  Enrolment: January 2013 – February 2014 
Median follow-up for OS: 8.9 months (NI), 6.8 months (DA)  
Cut-off dates for analyses: Clinical data cut-off was performed 
on June 24, 2014 after an unplanned interim database lock that 
showed a significant benefit in OS for nivolumab. This was 
followed by unblinding and amendment to allow patients 
enrolled in the dacarbazine group to receive nivolumab. 
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Hypothesis Superiority 
Funding Bristol-Myers Squibb International Corporation 
Treatment 
groups 
Intervention 
(n=210) 
Nivolumab 3mg per kilogram of body weight, solution for i.v. 
infusion every two weeks plus placebo every three weeks  
Control 
(n=208) 
Dacarbazine 1000 mg per square meter body-surface area, 
solution for i.v. infusion every three weeks plus placebo every 
two weeks 
Endpoints 
and 
definitions 
Overall survival 
(primary outcome) 
OS Time from randomisation to death from any cause 
Progression-free 
survival 
PFS Time from randomisation to first documented 
progression per RECIST 1.1, as determined by the 
investigator, or death due to any cause 
Objective  
response rate 
ORR Number of subjects with complete or partial response, 
per RECIST 1.1, divided by the number of randomised 
subjects assessed by investigators 
Overall survival 
based on PD-L1 
expression 
OS by 
PD-L1 
PD-L1 expression as predictive biomarker, measured 
by the endpoint OS based on PD-L1 expression level 
using an immunohistochemistry (IHC) assay 
Health-related 
quality of life 
HRQoL HRQoL as measured by mean changes from baseline 
in the EORTC-QLQ-C30 questionnaire V3 global 
health status/QoL composite scale and in the 
remaining EORTC QLQ-C30 scales 
Results and analysis 
Analysis  
description 
Efficacy analysis was performed in the population of patients who underwent 
randomisation (intention-to-treat population). 
OS and PFS were compared between treatment groups with two-sided log-rank test 
stratified according to PD-L1 status and metastasis stage. Hazard ratios were estimated 
using a stratified Cox proportional hazard model. Survival curves were estimated with 
Kaplan-Meier product-limit method.  
ORR was compared between treatment groups with two-sided Cochran-Mantel-
Haenszel test.  
Analysis  
population 
Key Inclusion Untreated, histologically confirmed unresectable Stage III or 
Stage IV melanoma (prior adjuvant or neoadjuvant melanoma 
therapy was permitted if completed six weeks prior to 
randomisation) 
Known BRAF wild-type as per regionally acceptable V600 
mutational status testing 
ECOG Performance Status of 0 or 1 
Key Exclusion Active brain or leptomeningeal metastases 
Ocular melanoma 
Active, serious autoimmune disease 
Serious or uncontrolled medical disorder 
Characteristics Median age (range): DA 66 years (26-87), NI 64 years (18-86) 
Gender: Females: DA 40%, NI 42% 
Metastasis stage: MO/M1a/M1b: DA 39%, NI 39%;  
M1c: DA 61%, NI 61% 
Prior systemic therapy: Adjuvant: DA 17%, NI 15%; 
Neoadjuvant DA 0.5%, NI 0.5% 
PD-L1 status: Positive: DA 36%, NI 35%;  
negative or indeterminate: DA 64%, NI 65% 
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Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Control 
(DA) 
Intervention 
(NI) 
Number of subjects N=208 N=210 
OS  
Median (months) 
95% CI 
 
10.8 
9.3-12.1 
 
not reached 
OS rate at one year 
% 
95% CI 
 
42.1 
33.0-50.9 
 
72.9 
65.5-78.9 
PFS  
Median (months) 
95% CI 
 
2.2  
2.1-2.4 
 
5.1  
3.5-10.8 
ORR 
% 
95% CI 
Complete response (%) 
Partial response (%) 
Stable disease (%) 
Progressive disease (%) 
Not determined (%) 
Duration of response 
(months) 
 
13.9  
9.5-19.4 
1.0 
13.0 
22.1 
48.6 
15.4 
6.0 
 
40.0 
33.3-47.0 
7.6 
32.4 
16.7 
32.9 
10.5 
not reached 
OS by PD-L1 status 
PD-L1 pos., Median (months) 
95% CI 
PD-L1 negative/indeterminate 
Median (months) 
95% CI 
 
12.4 
9.2-N.A. 
 
10.2 
7.6-11.8 
 
not reached 
 
 
not reached 
Health-related quality of life NA NA 
Effect 
estimate per 
comparison 
Comparison groups  Intervention vs. Control 
OS Hazard ratio for death 0.42 
99.79% CI 0.25-0.73 
P value <0.001 
PFS Hazard ratio for death  
or disease progression 
0.43 
95% CI 0.34-0.56 
P value <0.001 
ORR Odds ratio 4.06 
95% CI 2.52-6.54 
P value <0.001 
OS, PD-L1 positive Hazard ratio for death  0.30 
95% CI 0.15-0.60 
P value NA 
OS, PD-L1 negative/ 
indeterminate 
Hazard ratio for death  0.48 
95% CI 0.32-0.71 
P value NA 
Abbreviations: NA = not available; EORTC = European Organization for Research and Treatment of Cancer; QLQ-C30 
questionnaire version 3 = Quality of Life Questionnaire-Core 30; PD-L1 = Programmed death-ligand 1  
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Table 2: TRAEs according to grade, SAEs, AEs leading to discontinuation 
CA209-066 trial 
Grade (according  
to CTC version 4.0) Outcome (%) Nivolumab (n=206) Dacarbazine (n=205) 
Any grade Any AE 93.2 94.6 
Any grade  
treatment-related 
AEs 
occurring at least  
in ≥10% in either 
treatment arm 
Any AE 74.3 75.6 
Fatigue 19.9 14.6 
Pruritus 17.0 5.4 
Nausea 16.5 41.5 
Diarrhoea 16.0 15.6 
Rash 15.0 2.9 
Vitiligo 10.7 0.5 
Constipation 10.7 12.2 
Asthenia 10.2 12.2 
Vomiting 6.3 21.0 
Neutropenia 0 11.2 
Thrombocytopenia 0 10.2 
Grade 3 or 4 
treatment-related 
AEs 
occurring at least  
in ≥2% in either 
treatment arm 
Any AE 11.7 17.6 
Neutropenia 0 4.4 
Thrombocytopenia 0 4.9 
WBC count decreased 0 2.0 
Neutrophil count decreased 0 2.4 
Others Any grade SAE 31.1 38.0 
Grade 3 or 4 SAE 20.9 26.3 
Any grade treatment-related SAEs* 9.2 8.8 
Grade 3 or 4 treatment-related SAE 5.8 5.9 
Any grade AEs leading to 
discontinuation 
6.8 11.7 
Abbreviations: TRAE = treatment related adverse event; SAE = serious adverse event; AE = adverse event; WBC = white 
blood cell; * the listed treatment-related SAEs were reported in at least 2% of patients. 
 
In the CheckMate 066 phase III trial (CA209-066, [29]), nivolumab 3mg/kg 
i.v. every two weeks in combination with a placebo every three weeks was 
compared to dacarbazine 100mg/m2 i.v. every three weeks in combination with 
a placebo every two weeks in patients with unresectable, previously untreat-
ed stage III or IV melanoma without a BRAF mutation. Patients were required 
to have either no or only mild symptoms as assessed by ECOG performance 
status. Further, tumour tissue had to be available for PD-L1 biomarker anal-
ysis. Exclusion criteria included brain metastasis, ocular melanoma, serious 
or uncontrolled medical disorder and active autoimmune disease. Patients 
with conditions not expected to recur in the absence of an external trigger 
were permitted.  
418 adults were randomly assigned and stratified according to PD-L1 status 
and metastasis stage. Treatment continued until disease progression or unac-
ceptable toxicity occurred. Tumour response was assessed by the investigator 
according to RECIST 1.1 at nine weeks and then every 12 weeks.  
nivolumab vs. 
dacarbazine 
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Treatment continuation was allowed after disease progression for those who 
had a clinical benefit and no substantial AEs. At the end of the treatment pe-
riod, 46.1% of nivolumab-treated patients, but only 6.3% those treated with 
dacarbazine continued the study drug. 30.0% in the nivolumab and 54.8% in 
the dacarbazine group received subsequent systemic therapy, mostly with 
ipilimumab. 
At the time of database lock, the median follow-up for OS was 8.9 months with 
nivolumab and 6.8 months with dacarbazine. The primary endpoint, median 
OS, was not reached in patients with nivolumab and was 10.8 months with 
dacarbazine. At one year, the OS rate was significantly higher in the nivolu-
mab (73%) versus the dacarbazine group (42%; HR: 0.42; 99.79% CI: 0.25–
0.73; p<0.001). Moreover, median PFS was significantly longer with nivolu-
mab (5.1 months) than with dacarbazine (2.2 months; HR: 0.4; 95% CI: 0.34–
0.56; p<0.001). The ORR was also higher (40.0% vs. 13.9%; HR: 4.06; 95% 
CI: 2.52–6.54; p<0.001). An improved ORR was due to higher rates of par-
tial (32.4% vs. 13.0%), as well as complete responses (7.6% vs. 1.0%). As the 
median duration of response was not reached with nivolumab, a more durable 
response might be present, but the median follow-up time was short. A sub-
group analysis showed that nivolumab had improved OS compared to dacar-
bazine in both PD-L1 subgroups; its prognostic role thus remains to be de-
termined. Data on health-related quality of life has not been published yet. 
Any grade adverse events and serious adverse events occurred in 93% and 31% 
of patients treated with nivolumab in comparison to 95% and 38% in the da-
carbazine group. Overall, treatment-related AEs (TRAEs) of any grade were 
observed in 74% and in 76%, of which 12% and 18% were grade 3 or 4. TRAEs 
leading to discontinuation were reported in 6.8% of the patients with nivolu-
mab and 11.7% of those with dacarbazine. Treatment-related serious SAEs 
occurred in 9.2% and 8.8% respectively. There were no deaths attributed to 
the study drugs. The most frequently occurring TRAEs were fatigue, pruri-
tus and nausea in the nivolumab group, and nausea, vomiting and diarrhoea 
with dacarbazine. The most frequently occurring TRAEs with a potential im-
munological etiology in the nivolumab group were diarrhoea (16.0%), pruri-
tus (17.0%), rash (15.0%), vitiligo (10.7%) hypo-(4.4%) and hyperthyroidism 
(3.4%) and pneumonitis (1.5%). TRAEs with a potential immunological ae-
tiology of grade 3 or 4 occurring at least in ≥1% of patients with nivolumab 
were limited to increased ALT (1%) and diarrhoea (1%), all of them show-
ing a resolution of the event.  
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2.2 months 
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6.2 Efficacy and safety – further studies 
No further study results on nivolumab from phase II/III trials in the reviewed 
indication (first-line treatment in advanced melanoma) are available yet.  
For the indication of a subsequent line of treatment, the FDA relied on a 
phase III, randomised, open label study that compared nivolumab 3mg/kg 
every two weeks to the investigator’s choice of either dacarbazine or carbo-
platin and paclitaxel (CheckMate 037, CA209037, NCT01721746 [23]). The 
study was conducted in advanced melanoma patients who had progressed fol-
lowing ipilimumab therapy and a BRAF inhibitor, if they were BRAF V600 
mutation-positive. An interim analysis was conducted after the 120 patients 
randomised to nivolumab had completed six months of follow-up or had pro-
gressed. In the non-comparative analysis, the ORR with nivolumab was 31.7%, 
mainly due to partial responses (34/38). The durability of the response was 
uncertain, as 33/38 responding patients had ongoing responses ranging from 
2.6+ to 10+ months. Adverse reactions after a median exposure of 5.3 months 
included autoimmune-mediated organ toxicity, most often resulting in hypo-
thyroidism (8%), hyperthyroidism (3%) or involving the lungs (3.4%). Grades 
3 and 4 adverse reactions occurred in 42% of patients treated with nivolumab. 
The most common grade 3 or 4 adverse reactions occurring in 20% of nivo-
lumab-treated patients were abdominal pain, hyponatraemia, increased as-
partate aminotransferase and lipase.  
 
 
7 Estimated costs 
No cost estimates for nivolumab are available yet, neither for Austria nor for 
Germany. No cost estimates for nivolumab are available yet, neither for Aus-
tria nor for Germany. However, in Germany treatment costs comparable to 
those of ipilimumab or vermurafenib are expected, which would be about 
€20,000 per case [30]. According to UK Medicines Information, Opdivo® was 
launched in Japan at an annual cost of $143,000 per patient and analysts ex-
pect an annual cost of at least $110,000 in the US [31]. 
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8 Ongoing research 
According to ClinicalTrial.gov there is one ongoing phase III trial of nivolum-
ab in patients with previously untreated, unresectable or metastatic melanoma: 
 NCT01844505 (CheckMate 067, CA209-067; EudraCT 2012-005371-13) 
is a currently ongoing randomised, double-blind, multi-centre trial. It 
investigates nivolumab monotherapy in comparison with ipilimumab 
monotherapy and with a combination of nivolumab and ipilimumab. 
The primary endpoints are OS and PFS. The estimated primary com-
pletion date is September 2016.  
Other ongoing phase III trials investigate nivolumab in combination with ipili-
mumab in advanced melanoma patients with a BRAF mutation with or with-
out prior systemic therapy. In these trials, nivolumab plus ipilimumab were 
either followed or preceded by dabrafenib and trametinib (NCT02224781), 
or were administered with or without sargramostim (NCT02339571). 
Further ongoing phase III trials include previously treated or first-line ad-
vanced or metastatic non-small cell lung cancer (NCT01642004, NCT01673867, 
NCT02041533, NCT02066636), recurrent glioblastoma (NCT02017717), re-
current or metastatic head and neck carcinoma (NCT02105636), previously 
untreated or pre-treated advanced or metastatic renal cell carcinoma (NCT-
02231749, NCT01668784), and advanced or recurrent gastric cancer (NCT-
02267343).  
Nivolumab is also under investigation in phase II trials for advanced mela-
noma either as a subsequent line or in combination therapy and for further 
indications such as sarcomas, nasopharyngeal cancers, lymphoma, acute mye-
loid leukaemia, cervical cancer, pancreatic cancer, anal canal cancer, colorec-
tal cancer and ovarian cancer.  
 
 
9 Commentary 
For many years, the first-line therapy for patients with metastatic melanoma 
was restricted to cytotoxic therapy with dacarbazine, even despite the absence 
of a proven survival advantage [32]. With an increased characterisation of the 
molecular features of melanoma, new therapeutic options such as immuno-
therapy or targeted agents have become available. In most instances, newly 
approved drugs focused on melanoma harbouring BRAF mutations, e.g., ve-
murafenib or dabrafenib. Amongst recently approved drugs, only ipilimumab 
is indicated for previously treated and untreated patients regardless of their 
BRAF status [33].  
At the end of 2014, two further agents, that is, nivolumab and pembrolizu-
mab were approved by the FDA for patients who have progressed on ipili-
mumab and (if BRAF mutation-positive) a BRAF inhibitor. Accelerated ap-
proval by the FDA concerning nivolumab was based on the CheckMate 037 
trial, comparing nivolumab to chemotherapy in advanced melanoma. Results 
on the ORR and the duration of response were based on the data of a single-
arm, non-comparative, planned interim analysis; data on OS are not availa-
ble yet. 
one phase III trial of 
nivolumab in mono- and 
combination-therapy in 
untreated advanced 
melanoma 
phase III trials in range 
of other indications  
limited treatment 
options for advanced 
melanoma without 
BRAF mutation 
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In addition to the second-line setting, a phase III trial assessing nivolumab 
as a first-line treatment in patients with advanced melanoma without a BRAF 
mutation was conducted. In an interim analysis of data from CheckMate 066, 
nivolumab has shown a survival benefit compared to dacarbazine. Median 
PFS was extended by 2.9 months with nivolumab in comparison to dacarba-
zine, and the OS rate after one year was 73% vs. 42%. At the interim analy-
sis, median OS and the duration of response with nivolumab had not been 
reached yet, as response was durable over the (short) follow-up period. 
As health-related quality of life data has not been published with the result 
of the CheckMate 066 trial yet, it remains unknown whether the improve-
ment in survival will be achieved without a negative effect on the quality of 
life.  
Checkpoint inhibition is associated with a unique spectrum of irAEs that typ-
ically are transient, but can occasionally be severe or fatal. Generally, irAEs 
include dermatologic, gastrointestinal, hepatic and endocrine inflammatory 
events [34]. The most frequent TRAEs with potential immunological etiology 
occurring in the nivolumab arm of trial 066 were diarrhoea (16.0%), pruritus 
(17.0%), rash (15.0%), vitiligo (10.7%) hypo- (4.4%) and hyperthyroidism 
(3.4%) and pneumonitis (1.5%) [29]. TRAEs with potential immunological 
etiology of grade 3 or 4 occurring at least in ≥1% of patients in trial 066 
were limited to increased ALT and diarrhoea. All of them were showing a 
resolution, but the data set was limited. Grade 3 or 4 TRAEs were with 18% 
more frequent in the dacarbazine group than in patients treated with nivo-
lumab (12%), whereas serious grade 3 or 4 TRAEs were observed in 6% of 
patients in each group. Fewer patients with nivolumab discontinued therapy 
due to AEs (nivolumab 7% vs. dacarbazine 12%). In terms of AEs, any grade 
AEs were comparable between the two groups (93% vs. 95%). The most com-
mon TRAEs were fatigue, pruritus and nausea. 
Even though nivolumab was investigated only in patients without BRAF mu-
tations in the CheckMate 066 trial, there is no biologic rationale to restrict 
the use to patients with BRAF wild-type. Therefore, administration to all pa-
tients with melanoma in the first-line setting can be expected, once licensed.  
Despite these initial results demonstrating the improved efficacy of nivolu-
mab over dacarbazine, several questions remain. Firstly, dacarbazine was the 
standard first-line therapy of melanoma at the initiation of the CheckMate 
066 trial. However, ipilimumab, which is also manufactured by BMS, had 
not been licensed at the initiation of the trial, but has replaced dacarbazine 
as the preferred treatment in this setting. The comparative efficacy and safe-
ty of ipilimumab and nivolumab are thus not known yet.  
Another related question concerns whether the sequential or combined use 
of nivolumab with other drugs approved for advanced melanoma, foremost 
ipilimumab, will yield improved outcomes over single-agent therapy as in-
vestigated in the current phase III trial. Published results from a non-ran-
domised, open-label phase Ib study (NCT01024231), investigating either con-
current or sequenced treatment with nivolumab and ipilimumab in advanced 
melanoma patients, suggest that a combined administration achieves a high-
er level of efficacy than either of these agents alone [35; 36]. Since some au-
thors consider high-dose IL-2 followed by ipilimumab or a PD-1 or PD-L1 
antibody also as a viable option for first-line therapy, further uncertainties 
concerning first-line therapy arise [37]. 
nivolumab intended  
to be used first-line 
 
it has shown a survival 
benefit 
no quality of life data 
 
 
 
 
 
 
 
 
irAEs rare but data 
limited 
tested only in BRAF 
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extended use expected 
dacarbazine not 
standard of care for 
first-line therapy 
anymore 
comparative efficacy, 
sequential or combined 
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Since the time to response to ipilimumab is rather long, and the median time 
to response to nivolumab was only 2.1 months in the CheckMate 066 trial, 
there are discussions whether combination therapy can induce more rapid and 
durable responses than monotherapy [21; 38]. A currently ongoing phase III 
trial will help answer some of these questions. The CheckMate 067 trial com-
pares nivolumab monotherapy to ipilimumab monotherapy and to a combi-
nation of both agents in previously untreated patients. As the anti-PD-1 an-
tibody nivolumab and the anti-CTLA4 antibody ipilimumab are associated 
with immune-related toxicity, the possibly increased efficacy of the combina-
tion regimen would have to be weighed against the increased toxicity [4; 34; 
35; 39]. 
For patients with BRAF mutations, additional therapeutic options such as 
BRAF inhibitors (e.g., vemurafenib) exist. Even though immunotherapy is 
also the first-line therapy preferred by most authors, at least for patients with 
good performance status [22; 28; 37], trials assessing the combination of im-
munotherapy with targeted agents are underway. One phase I study assesses 
the combination of nivolumab and dabrafenib, of nivolumab and trametinib, 
and of a triple therapy of nivolumab, dabrafenib and trametinib in patients 
with BRAF- or NRAS-mutated metastatic melanoma (NCT02357732). Thus, 
further comparative trials are needed to help better characterise the optimal 
placement of nivolumab for patients with melanoma [5; 40].  
Against this background and since the drug has also been submitted to the 
FDA for far more frequent types of cancer and many ongoing trials are eval-
uating nivolumab for a variety of cancers (e.g., NSCLC), the initial price set 
for the drug is of utmost importance for the overall costs. No price estimates 
are currently available for Austria or Germany, but annual treatment costs 
comparable to ipilimumab can be expected. Since combination regimens of 
ipilimumab and nivolumab are likely in the near future, the costs for mela-
noma therapy would thus increase considerably. As nivolumab is currently 
under investigation for several other indications, its potential for off-label 
use is high.  
Due to the potential high price and the expected broad use of nivolumab, bi-
omarkers for predicting response to anti-PD1 antibodies would prove help-
ful in selecting patients profiting the most from these therapies. However, as 
assessed in the CheckMate 066 trial, no difference in outcomes was observed 
with regards to PD-L1 expression in the tumour. 
The comparative efficacy and safety in head-to-head trials, as well as the best 
treatment sequence and combination of the drugs available for the treatment 
of advanced melanoma, have yet to be determined. This holds true for pa-
tients with and without a BRAF mutation [21; 24; 40].  
 
immunotherapy  
first-line for most 
patients with advanced 
melanoma 
 
 
 
 
 
high potential for  
off-label use 
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